Three experimental Ebola vaccines are in development as British researchers spearhead the international response to the latest outbreak in Central Africa. Scientists at the University of Oxford and the London School of Hygiene and Tropical Medicine have confirmed that clinical trials are expected to begin within weeks, marking the most concerted vaccine drive since the 2014 West Africa epidemic.
The vaccines, developed in collaboration with the World Health Organization and the African Centres for Disease Control and Prevention, aim to target the Sudan strain of the virus, which has no approved vaccine. Existing Ebola vaccines, such as Merck’s Ervebo, protect only against the Zaire strain.
“This is a significant escalation in our preparedness,” said Dr. Catherine Green, head of the Oxford Vaccine Group. “We are leveraging the same platform technology that produced the Oxford AstraZeneca Covid-19 vaccine to accelerate development.”
The outbreak, first detected in a remote village in the Democratic Republic of Congo, has now spread to urban areas in neighbouring countries. As of Tuesday, the WHO reported 142 confirmed cases and 87 deaths, with a case fatality rate exceeding 60 percent. Health workers are struggling to contain the virus amid ongoing conflict and displacement in the region.
The UK’s role reflects a strategic investment in global health security. The government has allocated £50 million to the outbreak response, funding surveillance, contact tracing, and vaccine trials. The Foreign Office has also deployed rapid response teams to support local health systems.
“Timely intervention is critical,” said Professor Sir Jeremy Farrar, director of the Wellcome Trust. “Without effective vaccines, we risk a repeat of the 2014 catastrophe that claimed over 11,000 lives.”
The three candidate vaccines will enter Phase I safety trials in the UK and Brazil within 30 days. If successful, they will be fast-tracked for emergency use in affected areas. However, logistical challenges remain. Cold chain storage, particularly for vaccines requiring ultra-low temperatures, is difficult in the region’s tropical climate.
“We are working with partners to ensure that any approved vaccine can be deployed rapidly,” said Dr. Mike Ryan, executive director of the WHO Health Emergencies Programme. “The world is watching, and we must not fail.”
The outbreak has also raised concerns about the impact of misinformation. Social media platforms have been criticised for allowing the spread of false cures and conspiracy theories, undermining public trust in health authorities.
The UK Foreign Secretary has called for a coordinated global response, urging G7 nations to contribute additional funding and resources. “This is a test of our collective resolve,” he said in a statement. “Scientific collaboration, not isolation, will defeat this virus.”
